ACTION: a phase III multicentre cluster randomised clinical trial to assess whether the 'Respecting Choices Program' improves quality of life and symptoms of patients with advanced cancer

ancaster University (UK)0 个研究点目标入组 1,117 人开始时间: 2014年10月3日最近更新: 2023年1月9日

适应症

试验速览

2016 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/27059593 protocol 2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31672145 focus group results (added 04/11/2019) 2020 Other publications in https://pubmed.ncbi.nlm.nih.gov/31663183/ coping strategies of patients (added 07/10/2020) 2020 Results article in https://doi.org/10.1371/journal.pmed.1003422 results (added 02/12/2020) 2021 Other publications in https://pubmed.ncbi.nlm.nih.gov/33472621/ serious adverse event reporting procedures (added 22/01/2021) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36515362/ Healthcare use and healthcare costs (added 16/12/2022)

•Adult patients with advanced stages of lung or colorectal cancer. Patients need to have an estimated life expectancy of at least three months. The patients will be under the care of the oncologist at the participating hospitals.
•Histologically confirmed diagnosis of:
•1. Lung cancer:
•2. Small cell extensive disease/ Stage III or IV*
•3. Nonsmall cell stage III or IV*
•4. Colorectal cancer: Stage IV *
•*according to 7th edition of TNM classification and staging system
•5. Written informed consent to participate
•6. World Health Organisation performance status of 3 or under

•1. Age less than 18 years
•2. Unable to provide consent
•3. Unable to complete questionnaire in country's language
•4. Less than 3 months anticipated life expectancy
•5. Taking part in a research study that is evaluating palliative care services or communication strategies

发起方

ancaster University (UK)